The Korean College of Helicobacter and Upper Gastrointestinal Research proposed revised guidelines for the diagnosis and treatment of Helicobacter pylori infection in 2013. These new guidelines were developed using an adaptation process, and addressed the revised recommendations especially in the changes of indication and treatment of H. pylori infection in Korea. They included 19 statements: 11 on the indications for tests and treatment, four for the diagnosis, and four for the treatment. A critical difference between the new and previous guidelines was that the proposed treatment regimen was more detailed, in consideration of the increasing resistance to antibiotics in Korea. Although clarithromycin-containing triple therapy was proposed as the first-line treatment option, per the previous guidelines, a bismuth-based quadruple regimen was also proposed as an effective alternative. In the case of treatment failure following bismuth quadruple therapy, second-line treatment should be based on two or more antibiotics that had not been used previously. Several overseas guidelines -from America, Europe, Canada, Japan, and the Asia-Pacific region -have been published concerning H. pylori infection; they indicate regional differences in epidemiology, antibiotic susceptibility, and national health insurance systems. This review compares the guidelines for H. pylori infection among these regions. (Korean J Med 2015;89:157-168) 
UBT, urea breath test; SAT, stool antigen test; RUT, rapid urease test. In Japan, CLR-containing therapy regimen consists of lower dose of antibiotics than other countries; Japan: Proton pump inhibitor (PPI), amoxicillin 750 mg, and CLR 200 mg (or 400 mg) twice daily; Other countries: PPI, amoxicillin 1,000 mg, and CLR 500 mg twice daily. 
